<1.7 [4] , the patient received IVT with rtPA at 0.9 mg/kg (total dose 50 mg) 210 min after stroke onset. Shortly afterwards, the neurological status rapidly improved. On a follow-up blood examination, partial thromboplastin time (52.5 s) and INR (1.33) continued to be slightly elevated, while renal function was still impaired (creatinine clearance 27.8 ml/min). ICH could be ruled out by a follow-up cranial CT. Ultrasound examination of the cerebral vasculature was normal, as was echocardiography. Twenty-four hours after thrombolysis, creatinine clearance had increased above 30.0 ml/min, and treatment with dabigatran 110 mg twice daily was initiated. The NIHSS score at discharge was 1.
Discussion
To the best of our knowledge, this is the first report of a patient with acute ischemic stroke undergoing IVT despite rivaroxaban pretreatment. One could speculate that the favorable clinical outcome and the absence of bleeding complications in this case were related to the reduced dose of rivaroxaban as well as the relatively long interval between the last drug intake and IVT. Longer dosing intervals were also associated with a good functional outcome in stroke patients taking another direct oral anticoagulant (DOAC), dabigatran, before IVT [5] [6] [7] , whereas a fatal ICH occurred in another patient who underwent thrombolysis only 3 h after dabigatran intake [8] .
The conditions under which acute stroke patients taking DOAC should receive IVT remain unclear in the absence of sensitive coagulation tests [9] . Many of the current guideline committees have not updated their recommendations since the introduction of DOAC. These drugs are not addressed even in the most recent European guidelines [10] , whereas other updated guidelines [4] recommend discontinuing the rtPA administration until the results of accurate hematologic tests are known. However, IVT in rivaroxaban-treated patients may be considered if the plasma concentration of rivaroxaban is <100 ng/l or if anti-factor Xa activity is normal [11] . Importantly, the present case underlines that testing for established coagulation parameters in patients receiving DOAC is unreliable [11] and emphasizes the urgent need for sensitive bed-site tests during emergencies.
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